Prelude Therapeutics Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Prelude Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.00. The average 1-year stock price forecast is 109.97% higher than the current stock price, while the lowest is $6.00 (+57.48%) and the highest is $10 (+162.47%).

Price Target: $8.00 (+109.97%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$6.00	$8.00	$8.00	$10
Change	+57.48%	+109.97%	+109.97%	+162.47%

* Price targets were last updated on May 4, 2026.

Analyst Ratings

The average analyst rating for Prelude Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	2	2	2	2	2	3
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Kolbert D. Boral Capital	D. Boral Capital	Buy Initiates $9	Buy	Initiates	$9	+136.22%	May 4, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $5 → $8	Buy	Reiterates	$5 → $8	+109.97%	Apr 27, 2026
Reni Benjamin Citizens JMP	Citizens JMP	Buy Maintains $3 → $6	Buy	Maintains	$3 → $6	+57.48%	Mar 11, 2026

Financial Forecast

Revenue This Year

37.92M

from 12.14M

212.36%

from 12.14M

Revenue Next Year

53.33M

from 37.92M

40.65%

from 37.92M

EPS This Year

-0.95

from -1.29

EPS Next Year

-0.94

from -0.95

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	7.00M	12.14M	37.92M
Revenue Growth	-	-	-	-	73.43%	212.36%
Operating Income	-113.74M	-123.54M	-132.28M	-139.71M	-103.27M	-63.50M
Net Income	-111.69M	-115.44M	-121.83M	-127.17M	-99.50M	-22.87M
EPS	-	-	-	-	-1.29	-0.95
Free Cash Flow	-46.86M	-50.12M	-58.93M	-62.00M	-23.87M	32.00M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	104.6M
Avg	37.9M
Low	4.6M

Revenue Growth

Revenue Growth	2026	2027	2028
High	761.6%
Avg	212.4%
Low	-62.3%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.95
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-